ClinicalTrials.gg
CompletedNCT00485667TQTUpdated Feb 16, 2021

Phase 1 Thorough QT Study in Young Healthy Volunteers

A Phase 1 interventional study of SKY0402 and Moxifloxacin 400mg in Postoperative Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-16.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
273rd of 364
48 · median 70
Started
2007
with 6 others
Phase 1
21 of 364
4 open now
Registered
5th of 364
by date
Lead sponsor
22 of 364
Pacira Pharmaceuticals, Inc

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 273rd largest by enrollment, is one of 7 that started in 2007, is one of 21 in phase 1, and was the 5th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

A reduction in the postoperative need for opioids to enhance the recovery process and increase patient postoperative satisfaction.

Read the detailed description

Providing extended pain relief without the use of indwelling catheters is the basis for developing SKY0402. A formulation of bupivacaine, given as a single injection after surgery, that could provide adequate, continuous, and extended pain relief would greatly simplify postoperative pain management, reduce the need for repeated administration, and minimize break-through episodes of pain.

03

Conditions studied

  • Postoperative Pain

Keywords

  • pain
  • postoperative
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult Caucasian men or non-pregnant, non-lactating women between 18 and 40 years of age, inclusive.
  2. Healthy as judged by responsible physician with no abnormality identified on the medical and laboratory evaluation, including 12-lead and vital signs.
  3. Non-smoker in the previous 3 months.
  4. Body weight greater than or equal to 50 kg and within the range 19-29 kg/m2, inclusive.
  5. At screening and Run-in period each ECG should have:

    • Consistent sinus rhythm, (i.e. if greater than or equal to 2 ECGs are not sinusal at different time points the volunteer should not be included),
    • No clinically significant conduction disorder,
    • PR between 120 and 230 ms,
    • HR less than or equal to 100 beats/min and greater than or equal to 40 beats/min,
    • QRS \< 120 ms,
    • that can be consistently analysed,
    • QTcB less than or equal to 430 ms for males,
    • QTcB less than or equal to 450 ms for females

    If there are outlying values in the ECGs, the consistency of these values should be confirmed as follows:

    • If HR is between 40 and 44 bpm (inclusive) in 2 ECGs (of one triplicate) on more than one time point during Run-in, subject should not be selected. Conversely, this means that if HR is between 40 and 44 bpm at screening and/or on just one time-point-triplicate during Run-in, the volunteer can be selected.
    • If HR \< 40 bpm on a single occasion at screening or in Run-in period, subject should not be selected,
    • If PR interval is consistently out-of-range (\< 120 or > 230 ms) during Run-in period, i.e. in 2 out of 3 ECGs at one time point or in one ECG at more than one time point, the cardiologist needs to perform a manual measurement of this value. If the manual measurement confirms that PR is out-of-range, the volunteer must not be selected.
    • If QRS is consistently >120 ms during run-in period, i.e. in 2 ECGs of a triplicate or in 2 ECGs from 2 different time-points, the cardiologist needs to perform a manual measurement of this value. If the manual measurement confirms the QRS is out-of-range, the volunteer must not be selected.
    • If QTcB is out of range (QTcB >430 ms for males or >450 ms for females, or repeated demonstration of a QTcB interval >440 ms for females) even on a single occasion, it should be checked whether the heart rate is constant. If the HR is not constant and if the increase in QTcB is clearly due to hysteresis (e.g. on the immediate repeated ECG with consistent HR the QTcB is back to normal), then the volunteer can be selected. If the HR is constant and the QTcB is still out-of-range, the cardiologist needs to perform a manual measurement and calculation of the QTcB. If the QTcB is normal on manual measurement, the volunteer can be selected. If the QTcB is abnormal on manual measurement without acceptable cause, the volunteer must not be selected, even if the QTcB is outlying on one single ECG.

    The final decision to include / not include a volunteer based on protocol ECG criteria lies with the cardiologist assessing the Run-in ECGs.

  6. Signed and dated written prior to admission to the study.
  7. The subject is able to understand and comply with protocol requirements, instructions, and protocol-stated restrictions.
  8. A female subject may be entered into the study if she is:

    • female defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile, e.g. appropriate age and history of vasomotor symptoms. However; if indicated, this should be confirmed by estradiol and FSH levels consistent with menopause (according to local laboratory ranges).
    • Pre-menopausal females with a documented hysterectomy (medical report verification) and/or bilateral oophorectomy. In the case of oophorectomy alone, only acceptable when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    • Females of must use one of the following methods of :

      • Abstinence
      • Surgical sterilisation (tubal ligation)
      • use oral contraceptives, injectable progesterone, or subdermal implants
      • use double barrier method consisting of spermicide in addition to using a condom, or having another form of contraception such as an intrauterine device, diaphragm, or cervical cap.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease.
  2. History of clinically significant syncope.
  3. Family history of sudden death.
  4. Family history of premature cardiovascular death.
  5. Clinically significant history or family history of congenital long syndrome (e.g. Romano-Ward syndrome, Jervell and Lange-Nielson syndrome) or Brugada's syndrome.
  6. History of clinically significant arrhythmias (especially ventricular arrhythmias, atrial fibrillation, or recent conversion from atrial fibrillation).
  7. Complete bundle branch block / sinus node dysfunction.
  8. Conditions predisposing the volunteer to electrolyte imbalances (e.g. altered nutritional states, chronic vomiting, anorexia nervosa, bulimia nervosa).
  9. Any pathology or abnormality with possible influence on the ECGs.
  10. Clinically significant dermatological disease including history of drug-induced skin rash.
  11. History of clinically significant psychiatric illness.
  12. History of gastro-intestinal surgery except appendectomy, herniotomy and cholecystectomy.
  13. History of chronic inflammation of gastro-intestinal tract.
  14. History of tendinopathy with fluoroquinolone.
  15. Subjects with vital signs measurements as follows:

    • Supine heart rate outside the 40 to 100 beats/min range,
    • Standing heart rate outside the 40 to 125 beats/min range,
    • Supine systolic blood pressure outside the 80 to 140 mmHg range
    • Supine diastolic blood pressure outside the 40 to 95 mmHg range.
  16. Subjects with a symptomatic drop in systolic blood pressure of > 20 mmHg and diastolic > 10 mmHg at screening.
  17. A positive pre-study 1 \& 2 antibodies, surface antigen, and/or antibody result.
  18. Positive serum pregnancy tests for women of .
  19. Subjects with a confirmed positive pre-study urine drugs of abuse / alcohol breath test.
  20. History or evidence of drug or alcohol abuse within 18 months of study start.
  21. Abuse of alcohol defined for males as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units; or for females defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units. One unit is equivalent to a half-pint(220 mL) of beer or 1 (25 ml) measure of spirits or 1 glass (125 ml) of wine.
  22. Use of prescribed medication during the two weeks before the baseline day in Period 1 and use of OTC drugs (including herbal remedies and minerals) in the week before the baseline ECG day in Period 1 (or 14 days if the drug has enzyme affecting properties), unless in the opinion of the Investigator and Sponsor the medication will not interfere with the study procedures or compromise subject safety. Use of medications which are known to carry a risk of causing Torsades de Pointes is not allowed within 14 days or 10 times the elimination half life (whichever is longer) before the baseline ECG day in Period 1. Use of vitamins is not allowed within 48 hours before the baseline ECG day in Period 1. Oral drugs for women of childbearing potential and occasional use of paracetamol (up to 2 g/day) for pain and fever relief is allowed.
  23. History or presence of allergy to the study drugs or drugs in their respective classes, or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
  24. A known history of to drugs, specifically to any component of the study medication, or history of hypersensitivity to moxifloxacin or any member of the quinolone class of antimicrobial agents.
  25. The subject has eaten grapefruit, grapefruit juice, Seville oranges, watercress, broccoli, brussel sprouts or cabbage within seven days before the baseline ECG day in Period 1.
  26. Participation in a study with an drug within 90 days prior to the baseline ECG day in Period 1.
  27. Blood donation or blood loss within 90 days prior to the baseline ECG day in Period 1.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Moxifloxacin tablet

    Drug: SKY0402 · Drug: Moxifloxacin 400mg · Drug: Placebo injection

  • Experimental
    Placebo tablet

    Drug: SKY0402 · Drug: Placebo injection · Drug: Placebo tablet

  • Experimental
    SKY0402 300mg

    Drug: SKY0402 · Drug: Moxifloxacin 400mg · Drug: Placebo tablet

  • Experimental
    SKY0402 450mg

    Drug: SKY0402 · Drug: Moxifloxacin 400mg · Drug: Placebo tablet

  • Placebo comparator
    Placebo injection

    Drug: Moxifloxacin 400mg · Drug: Placebo injection · Drug: Placebo tablet

Interventions

06

What researchers measure

Primary outcomes

  1. ECG findings using the best heart rate correction method

    Time frame: Up to 96 hours

Secondary outcomes

  1. QT/QTc interval data variations from baseline

    Time frame: up to 96 hours

07

Study locations

1 site
  • Richmond Pharmacology Ltd
    London, SW19 0RE, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Aug 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2007
First posted
Jun 13, 2007
Start
Jun 2007
Primary completionActual
Aug 2007
CompletionActual
Aug 2007
Last update
Feb 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00485667
Collaborators
Richmond Pharmacology Limited
First posted
Jun 13, 2007
Start date
Jun 2007
Primary completion
Aug 2007
Completion
Aug 2007
Last update
Feb 16, 2021

Study contacts

Jorg Taubel, MD MFPM
principal investigator · Richmond Pharmacology Limited

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Moxifloxacin

Start the discussion